BioInvent International
LUND, SE / ACCESSWIRE / December 8, 2021 / BioInvent International (STO:BINV)
- BioInvent's pipeline expanding to four drug candidates in five clinical trials
Lund, Sweden - December 8, 2021 - BioInvent International AB ("BioInvent") (Nasdaq Stockholm: BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, today announces it has submitted a Clinical Trial Application (CTA) for the novel, fully human FcyRIIB-blocking antibody, BI-1607.
BI-1607 targets FcyRIIB but is modified in its Fc region to alter its affinity for Fc receptors. By selectively blocking FcyRIIB, BI-1607 enhances the activity of other therapeutic monoclonal antibodies, whose mechanism-of-action involves depletion of tumors or immune suppressive cells. Understanding the biology of FcR/Fc interactions was essential for generating BI-1607, which has a clearly differentiated profile from BioInvent's lead drug candidate BI-1206.
BioInvent intends to explore the activity of BI-1607 in advanced solid tumors and antibody combinations supported by strong preclinical data.
"We are pleased to have completed this step in the development. BI-1607 is a very promising approach given its ability to enhance anti-cancer immunity and approval of the CTA will expand the BioInvent pipeline to four drug candidates in five clinical trials, further underlining the productivity of our technology platform," said Martin Welschof, CEO of BioInvent.
About BioInvent
BioInvent International AB (Nasdaq Stockholm: BINV) is a clinical-stage biotech company that discovers and develops novel and first-in-class immuno-modulatory antibodies for cancer therapy. In addition to BI-1607, the company has three drug candidates in four ongoing clinical programs in Phase 1/2 trials for the treatment of hematological cancer and solid tumors, respectively. The Company's validated, proprietary F.I.R.S.T™ technology platform simultaneously identifies both targets and the antibodies that bind to them, generating many promising new drug candidates to fuel the Company's own clinical development pipeline or for additional licensing and partnering.
The Company generates revenues from research collaborations and license agreements with multiple top-tier pharmaceutical companies, as well as from producing antibodies for third parties in the Company's fully integrated manufacturing unit. More information is available at www.bioinvent.com.
For further information, please contact:
Cecilia Hofvander
Senior Director Investor Relations
+46 (0)46 286 85 50
cecilia.hofvander@bioinvent.com
BioInvent International AB (publ)
Co. Reg. No. Org nr: 556537-7263
Visiting address: Ideongatan 1
Mailing address: 223 70 LUND
Phone: +46 (0)46 286 85 50
www.bioinvent.com
SOURCE: BioInvent International
View source version on accesswire.com:
https://www.accesswire.com/676499/BioInvent-has-Submitted-a-CTA-for-a-Phase-12a-trial-of-BI-1607-a-Novel-anti-FcyRIIB-Antibody-for-the-Treatment-of-Patients-with-Solid-Tumors
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
MicroVision Collaborates with Leading Photonics Ecosystem to Acquire FMCW Lidar Business10.11.2025 22:05:00 CET | Press release
REDMOND, WA / ACCESS Newswire / November 10, 2025 / MicroVision, Inc. (NASDAQ:MVIS), a technology pioneer delivering advanced perception solutions in autonomy and mobility, today announced that it had entered into an agreement to acquire the business and assets of Scantinel Photonics GmbH, a developer of 1550nm frequency-modulated continuous wave, or FMCW, lidar technology targeted for initial application in the commercial vehicle market. In connection with the acquisition, MicroVision is collaborating with certain funding and strategic partners to accelerate productization and commercial opportunities. Scantinel Photonic's core technology was developed with financial backing and key support from Zeiss Group, a German manufacturer of optical systems and optoelectronics; Scania, a Swedish commercial trucking OEM; and PhotonVentures, a deep tech venture capital firm purely focused on the key enabling technology of integrated photonics and a strategic partner of PhotonDelta, a Dutch distr
Loop Industries Executes a Multi-Year Offtake Agreement With Nike, the Global Leader in Athletic Footwear and Apparel10.11.2025 14:00:00 CET | Press release
Nike signs on as the anchor customer for the Infinite Loop™ India manufacturing facility. Multi-year offtake agreement secures supply of Twist™, Loop's branded, virgin-quality polyester resin made exclusively from textile waste. Twist™ will feature full traceability via Loop's proprietary chemical tracer technology, providing verifiable textile to textile recycled content. Infinite Loop India is a joint venture between Loop industries and Ester industries. MONTRÉAL, QUEBEC / ACCESS Newswire / November 10, 2025 / Loop Industries, Inc. (Nasdaq:LOOP) ("Loop"), a clean technology company accelerating the circular economy, today announced a multi-year offtake agreement with NIKE, Inc. ("Nike"), the global leader in athletic footwear and apparel. Under the agreement, Loop will supply Twist™, its virgin-quality circular polyester resin made exclusively from textile waste, establishing Nike as the anchor customer for the Infinite Loop™ India manufacturing facility which is being constructed in
EverC Introduces AI-powered Scam Network Intelligence to Disrupt Fraud Online10.11.2025 09:00:00 CET | Press release
The solution maps the entire scam infrastructure across e-commerce, social media, and payments marketplaces NEW YORK CITY, NY / ACCESS Newswire / November 10, 2025 / EverC, now part of G2 Risk Solutions, today announced Scam Network Intelligence, an AI-powered solution that exposes scam networks to help marketplaces detect and disrupt fraud. Scams are now the largest driver of fraud losses globally, accounting for 23% of fraudulent transactions in 2024, with losses reaching $1 trillion. To address the rise in fraud in the payments and e-commerce space, the Scam Network Intelligence solution gives marketplaces visibility into the networks behind online scams. The solution has the ability to identify and map how scammers reach and engage their victims-across ad networks, fake support portals, messaging apps, and social media networks. By identifying scam clusters early, the payments ecosystem can reduce blind spots and prevent consumer harm. "Fraud is increasingly sophisticated and flows
Karbon-X Expands Blue Carbon Leadership with New Restoration Project in Guinea7.11.2025 14:00:00 CET | Press release
New initiative in the Konkouré Delta builds on Senegal's success, advancing coastal restoration, biodiversity, and community resilience across West Africa. CONAKRY, GN / ACCESS Newswire / November 7, 2025 / Building on the success of its 7,000-hectare mangrove reforestation project in Senegal-which has already generated an estimated 2.8 million tonnes of CO₂ reductions and measurable community benefits-Karbon-X Corp. (OTCQX:KARX) ("Karbon-X" or the "Company") is expanding its blue carbon leadership into the Konkouré Delta of Guinea, as blue carbon emerges as a critical frontier for climate investment and coastal resilience. Developed through ALLCOT - A Karbon-X Company, the project development and advisory arm of Karbon-X, the initiative will replicate and scale the proven model from Senegal, enhancing biodiversity, shoreline protection, and sustainable livelihoods across West Africa. Mangroves are more than trees; they are natural shields protecting coastlines, nurseries for marine li
Innodata Reports Third Quarter 2025 Results6.11.2025 22:30:00 CET | Press release
Revenue up 20% Year-Over-Year Reiterates Prior Guidance of 45% or More YoY Growth in 2025 Anticipates Transformative Growth in 2026 Based on New Wins and Strong Momentum NEW YORK CITY, NY / ACCESS Newswire / November 6, 2025 / INNODATA INC. (Nasdaq:INOD) today reported results for the third quarter ended September 30, 2025. Revenue of $62.6 million for the three months ended September 30, 2025, representing 20% year-over-year organic revenue growth. Revenue of $179.3 million for the nine months ended September 30, 2025, representing 61% year-over-year organic revenue growth. Adjusted EBITDA of $16.2 million for the three months ended September 30, 2025, an increase of $2.3 million, or 17%, from $13.9 million in the same period last year.* Adjusted EBITDA of $42.2 million for the nine months ended September 30, 2025, an increase of $21.8 million, or 106%, from $20.4 million in the same period last year.* Net income of $8.3 million, or $0.26 per basic share and $0.24 per diluted share, f
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom